WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 14, 479-494. Review Article ISSN 2277–7105

ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE: CURRENT APPLICATIONS, OPPORTUNITIES, CHALLENGES, AND FUTURE PERSPECTIVES

***[1]Mr. Pratik D. Kachare, [2]Ms. Shruti J. Kadam, [3]Mr. Pankaj Kalel, [4]Mr. Pradeep Jadhav, [5]Mrs. Anuradha Salunkhe**

Satara College of Pharmacy, Satara, Maharashtra, India.

Article Received on 15 June 2026,
Article Revised on 05 July 2026,
Article Published on 16 July 2026,

https://doi.org/10.5281/zenodo.21357975

***Corresponding Author**
Mr. Pratik D. Kachare
Satara College of Pharmacy, Satara, Maharashtra, India.

How to cite this Article: *[1]Mr. Pratik D. Kachare, [2]Ms. Shruti J. Kadam, [3]Mr. Pankaj Kalel, [4]Mr. pradeep Jadhav, [5]Mrs. Anuradha Salunkhe. (2026). Artificial Intelligence In Pharmacovigilance: Current Applications, Opportunities, Challenges, And Future Perspectives. World Journal of Pharmaceutical Research, 15(14), 479–494.

ABSTRACT

Pharmacovigilance (PV) is a critical component of healthcare systems that aims to ensure the safe and rational use of medicines through the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs). Large volumes of safety data that contradict traditional pharmacovigilance methods have been produced by the quick growth of healthcare databases, electronic health records, spontaneous reporting systems, biomedical literature, and social media platforms. A promising technology for improving pharmacovigilance efforts is artificial intelligence (AI), which includes machine learning (ML), deep learning (DL), natural language processing (NLP), and generative AI. AI-driven methods increase the effectiveness and precision of medication safety monitoring by enabling automated case processing, signal detection, literature screening, duplication identification, and predictive safety evaluations. Widespread adoption is still hampered by issues like poor data quality, algorithmic bias, explainability issues, privacy concerns, and regulatory difficulties. The principles and uses of AI in pharmacovigilance are covered in this study, along with key potential and difficulties, existing regulatory perspectives, and future directions for AI-enabled drug safety monitoring.

KEYWORDS: Artificial Intelligence; Pharmacovigilance; Adverse Drug Reactions; Machine Learning; Deep Learning; Natural Language Processing; Signal Detection; Drug

Safety.

1. INTRODUCTION

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. The aims of pharmacovigilance include improving patient care and safety and promoting the rational and safe use of medicines.[1] Worldwide, adverse drug reactions (ADRs) are linked to substantial morbidity, mortality, and economic burden, making them a serious public health concern. ADRs often lead to longer hospital stays and higher medical expenses, underscoring the necessity of efficient pharmacovigilance systems.[2,3]

Individual Case Safety Reports (ICSRs) are manually reviewed and spontaneous reporting mechanisms are the mainstays of traditional pharmacovigilance systems. However, the prompt discovery of drug safety issues may be compromised by these systems' limitations, which include underreporting, delayed signal detection, insufficient information, and significant human resource requirements.[4,5] Massive amounts of diverse safety data from electronic health records, biomedical literature, social media platforms, and real-world evidence databases have been produced by the digital transformation of healthcare. Advanced computational techniques are required because traditional pharmacovigilance methods are becoming insufficient for effectively processing and interpreting such large-scale datasets.[6] Artificial intelligence (AI) has become a game-changing technology that can mimic human cognitive processes like learning, thinking, and decision-making. Pharmacovigilance tasks can be automated, safety signals can be identified, information can be extracted from unstructured data sources, and adverse drug reactions can be predicted with the help of machine learning, deep learning, and natural language processing.[6,7]

Even with the prospective uses of AI in pharmacovigilance, there are still a number of obstacles to overcome, including as problems with data quality, algorithmic bias, transparency, ethical dilemmas, and regulatory approval. Therefore, for AI to be successfully included into contemporary pharmacovigilance systems, a thorough grasp of both its advantages and disadvantages is necessary.[8,9] The purpose of this study is to give a thorough overview of AI applications in pharmacovigilance, talk about related opportunities and difficulties, and investigate potential directions for AI-enabled drug safety monitoring in the future.

2. Fundamentals of Artificial Intelligence and Its Relevance to Pharmacovigilance

2.1 Definition and Evolution of Artificial Intelligence

Artificial intelligence (AI) refers to computational systems capable of performing tasks that normally require human intelligence, including learning, reasoning, problem-solving, and decision-making. In healthcare, AI technologies have evolved rapidly and are increasingly being applied to improve clinical decision-making, data analysis, and patient safety monitoring.[10,11]

2.2 Machine Learning in Pharmacovigilance

Machine learning (ML) is a subset of AI that enables computer systems to learn from data and improve performance without explicit programming. ML algorithms have demonstrated significant utility in pharmacovigilance by facilitating adverse event detection, signal identification, literature screening, and risk prediction through the analysis of large and complex datasets.[11,12]



Figure 1: Classification of Artificial Intelligence Technologies and Their Applications in Pharmacovigilance.

2.3 Deep Learning in Pharmacovigilance

Deep learning (DL), an advanced branch of machine learning, employs artificial neural networks with multiple hidden layers to analyze complex and high-dimensional datasets. Deep

learning approaches have shown promising applications in extracting information from electronic health records, spontaneous reporting systems, and biomedical literature for adverse drug reaction identification and prediction.[12,13]

2.4 Natural Language Processing in Pharmacovigilance

Natural language processing (NLP) enables computers to interpret and process human language from unstructured data sources. In pharmacovigilance, NLP techniques are widely used to extract safety information from clinical narratives, scientific publications, social media posts, and Individual Case Safety Reports (ICSRs), thereby reducing manual workload and improving operational efficiency.[11,14]

2.5 Generative Artificial Intelligence and Large Language Models

Generative artificial intelligence and large language models (LLMs) represent recent advances in AI capable of generating human-like text, summarizing information, and assisting in knowledge extraction. These technologies have shown potential applications in pharmacovigilance, including automated case narrative generation, literature summarization, and decision support, although concerns regarding accuracy, explainability, and regulatory acceptance remain.[11,15]

2.6 Relevance of Artificial Intelligence to Modern Pharmacovigilance

For effective processing and interpretation, sophisticated computational techniques are required due to the growing amount, diversity, and complexity of pharmacovigilance data. AI-driven techniques can assist proactive drug safety surveillance and supplement conventional pharmacovigilance procedures by quickly analyzing vast datasets, finding hidden patterns, spotting new safety signals, and facilitating evidence-based decision-making.[11-13]

3. Data Sources for AI-Based Pharmacovigilance

3.1 Overview of Data Sources

Pharmacovigilance powered by artificial intelligence (AI) depends on the availability of sizable, varied, and high-quality datasets for identifying, evaluating, and forecasting adverse drug reactions (ADRs). Comprehensive safety surveillance and the detection of new drug safety signals are made possible by the integration of data from spontaneous reporting systems, electronic health records, biological literature, social media platforms, and real-world evidence databases.[16,17]



Figure 2: Major Data Sources for AI-Based Pharmacovigilance.

3.2 Spontaneous Reporting Systems (SRS)

The foundation of pharmacovigilance is spontaneous reporting systems (SRSs), which are made up of voluntarily submitted reports of suspected adverse drug reactions from patients, medical professionals, and pharmaceutical corporations. Important SRS databases, such as the U.S. Food and Drug Administration and VigiBase from the Uppsala Monitoring Center The Adverse Event Reporting System (FAERS) offers useful information for benefit-risk analysis and signal discovery. These massive datasets can be effectively analyzed by AI and machine learning techniques to find previously undetected safety signs.[16-18]

3.3 Electronic Health Records (EHRs)

Diagnoses, test results, prescription histories, and treatment results are among the structured and unstructured clinical data found in electronic health records (EHRs). EHRs offer real-world clinical data that can help identify adverse medication occurrences in ordinary clinical practice and supplement spontaneous reporting systems. In order to extract useful safety information from EHR data, machine learning and natural language processing algorithms have demonstrated significant promise.[17-19]

3.4 Biomedical Literature Databases

A wealth of information about adverse drug reactions, drug interactions, and safety issues

raised in scientific articles can be found in biomedical literature databases like PubMed. Manual literature screening is frequently time-consuming and labor-intensive. Text-mining and natural language processing techniques can automate literature surveillance and increase the effectiveness and uniformity of pharmacovigilance operations.[20,21]

3.5 Social Media and Patient Forums

Online patient communities and social media platforms have become significant providers of practical safety advice. On social media and health forums, patients often discuss their experiences with pharmaceutical use, side effects, and treatment results. AI methods, especially sentiment analysis and natural language processing, can make it easier to extract safety information from these unstructured data sources and may help identify possible safety warnings earlier.[20-22]

3.6 Real-World Evidence (RWE) Databases

Databases of real-world evidence (RWE) include data from observational research, insurance claims, patient registries, and medical records. These databases offer insightful information about pharmaceutical use and safety results in a variety of patient demographics in practical settings. AI integration with RWE data has the potential to enhance benefit-risk assessments, risk prediction, and signal identification, facilitating more efficient pharmacovigilance decision-making.[17,23]

4. Applications of Artificial Intelligence in Pharmacovigilance

4.1 Automated Case Processing and ICSR Management

By automating case intake, data extraction, coding, duplication identification, and case prioritizing, artificial intelligence has greatly increased the effectiveness of processing Individual Case Safety Reports (ICSRs). Algorithms for machine learning and natural language processing can extract pertinent data from both structured and unstructured data sources, decreasing manual labor and enhancing case processing accuracy and consistency.[24,25]

4.2 Adverse Drug Reaction Signal Detection

A key component of pharmacovigilance is signal detection, which entails finding hitherto undiscovered connections between medications and adverse occurrences. Large spontaneous reporting databases can be analyzed by AI-based techniques to find underlying patterns that traditional disproportionality methods might miss. The sensitivity and timeliness of safety signal identification have been shown to be significantly improved by machine learning

methods.[25,26]

4.3 Literature Screening and Information Extraction

A major obstacle to manual literature surveillance is the ongoing expansion of biomedical literature. Adverse event data can be extracted from scientific papers, pertinent safety information can be found, and literature screening can be automated using natural language processing and text-mining techniques. These tools increase productivity and shorten the time needed to monitor pharmacovigilance literature.[27]

4.4 Social Media Monitoring and Patient-Reported Adverse Events

On social media sites and online health forums, patients are increasingly sharing their experiences with pharmaceutical use and side effects. AI methods, especially sentiment analysis and natural language processing, can extract useful safety information from these unstructured data sources and may help identify possible adverse drug reactions and new safety issues earlier.[28,29]

4.5 Predictive Safety Analytics and Risk Prediction

On social media sites and online health forums, patients are increasingly sharing their experiences with pharmaceutical use and side effects. AI methods, especially sentiment analysis and natural language processing, can extract useful safety information from these unstructured data sources and may help identify possible adverse drug reactions and new safety issues earlier.[30]

4.6 Regulatory Decision Support and Benefit-Risk Assessment

By combining data from various sources and producing evidence-based insights about drug safety, artificial intelligence can assist regulatory decision-making. AI-powered platforms could help regulatory bodies make prompt and well-informed choices about pharmaceuticals, prioritize safety alerts, and facilitate benefit-risk assessment.[30]

5. Opportunities of Artificial Intelligence in Pharmacovigilance

5.1 Improved Efficiency and Automation

Case intake, literature screening, data extraction, and coding are just a few of the labor-intensive and repetitive pharmacovigilance tasks that artificial intelligence can automate. Automation makes it possible to manage massive amounts of safety data more effectively by reducing manual labor, minimizing human error, and increasing the speed and consistency of

pharmacovigilance procedures.[31,32]

5.2 Enhanced Signal Detection and Early Risk Identification

Large and diverse datasets can be analyzed by AI algorithms to find hidden patterns and flag possible safety signals earlier than with traditional techniques. Early detection of adverse medication responses enhances patient safety outcomes and enables prompt regulatory measures.[33,34]

5.3 Real-Time Monitoring and Big Data Analytics

Real-time medication safety monitoring is made possible by the integration of AI with electronic health records, spontaneous reporting systems, social media platforms, and real-world evidence databases. Big data analytics powered by AI can assist proactive pharmacovigilance tactics and continuously assess new safety information.[35,36]

5.4 Improved Decision-Making and Benefit-Risk Assessment

By combining data from many sources and producing evidence-based insights, machine learning and predictive analytics can help evaluate benefit-risk profiles. AI can help make clinical and regulatory decisions with greater knowledge.[37,38]

5.5 Personalized and Precision Pharmacovigilance

By recognizing patient-specific risk variables and forecasting an individual's propensity to adverse drug reactions, AI technologies have the potential to support precision pharmacovigilance. Personalized risk assessment could enhance drug safety and facilitate customized treatment plans.[39,40]

6. Challenges and Limitations of Artificial Intelligence in Pharmacovigilance

6.1 Data Quality and Data Heterogeneity

The quality, consistency, and completeness of input data determine how well artificial intelligence systems perform in pharmacovigilance. Information about pharmacovigilance is gathered from a variety of sources, including social media platforms, electronic health records, biological literature, and spontaneous reporting systems. These databases frequently include unstructured content, inconsistent terminology, duplicate entries, and missing values. These problems may limit the dependability of AI-based pharmacovigilance systems and lower model accuracy.[41,42]

6.2 Algorithmic Bias and Limited Generalizability

Biases found in training datasets may be learned and replicated by AI algorithms. These biases may result from geographical variations in healthcare systems, demographic imbalance, or underreporting. Because of this, model performance may differ among groups, decreasing generalizability and perhaps resulting in erroneous adverse drug reaction detection.[43,44]

6.3 Lack of Explainability and Transparency

Many deep learning and machine learning models function as "black-box" systems, meaning that the internal decision-making process is difficult to understand. The regulatory approval and clinical uptake of AI-based pharmacovigilance tools are hampered by this lack of transparency, which also erodes trust among medical professionals.[45]

6.4 Ethical and Privacy Concerns

Pharmacovigilance AI systems need access to private patient information from real-world databases and clinical records. Concerns about informed permission, data confidentiality, privacy protection, and the moral use of health information are brought up by this. It is crucial to ensure safe data management and adherence to privacy laws.[46,17]

6.5 Regulatory and Implementation Challenges

As of right now, the development and validation of AI-based pharmacovigilance systems need a globally unified regulatory framework. Large-scale deployment is constrained by variations in evaluation techniques, validation standards, and regulatory requirements. To guarantee the safe and reliable application of AI in medication safety monitoring, clear rules are required.[48,49]

6.6 Need for Human Oversight

In pharmacovigilance, artificial intelligence should complement human expertise rather than replace it. Making final regulatory judgments, verifying causality, and assessing safety signals all depend on expert opinion. Human supervision guarantees AI systems' accuracy, therapeutic applicability, and moral application.[49,50]

7. Regulatory Perspectives on Artificial Intelligence in Pharmacovigilance

7.1 Global Regulatory Interest

Artificial intelligence applications in pharmacovigilance for risk assessment, safety monitoring, and signal detection are being investigated by regulatory bodies more and more.

But its incorporation into standard regulatory procedures is still developing.[51,52]

7.2 Need for Standardization

Standardized frameworks are desperately needed for pharmacovigilance AI system reporting, performance assessment, and validation. Global implementation is limited by the absence of consistent norms.[53]

7.3 Key Regulatory Concerns

Safety, accountability, data integrity, openness, and interpretability of AI systems used in drug safety monitoring are important regulatory priority areas.[54]

7.4 Future Regulatory Development

It is anticipated that future regulatory frameworks would incorporate audit procedures, formal validation paths, and ongoing post-deployment monitoring of AI-based systems.[55]

8. Future Perspectives of Artificial Intelligence in Pharmacovigilance

8.1 Real-Time Pharmacovigilance Systems

AI-enabled technologies will improve early detection of adverse medication responses by enabling continuous and real-time monitoring of global drug safety data.[56]

8.2 Predictive Pharmacovigilance

In order to enable preventive interventions, future AI models will concentrate on detecting high-risk patient populations and anticipating harmful medication reactions before they happen.[57]

8.3 Role of Generative AI

Automated case story writing, literature summary, and regulatory documentation may be supported by generative AI and huge language models, but their safe application requires rigorous validation.[58]

8.4 Precision Pharmacovigilance

By combining genetic, clinical, and demographic data to forecast individual risk profiles, AI will enable customized drug safety monitoring.[57,59]

8.5 Global Integrated Systems

Future pharmacovigilance systems will connect global databases to enable real-time

international collaboration and faster safety signal exchange.[56,60]

9. CONCLUSION

Artificial intelligence is emerging as a powerful tool in pharmacovigilance by improving the detection, assessment, and monitoring of adverse drug reactions. By processing vast amounts of diverse healthcare data, AI-based solutions increase efficiency and make it possible to identify safety warnings more quickly and accurately. Pharmacovigilance is now more proactive than reactive thanks to these technologies, which also provide real-time monitoring, predictive analytics, and better regulatory decision-making.

Despite these benefits, there are a number of obstacles to using AI in pharmacovigilance, such as problems with data quality, algorithmic bias, a lack of transparency, ethical dilemmas, and legal constraints. These difficulties demonstrate the necessity of strong validation frameworks, uniform standards, and ongoing human supervision to guarantee the secure and dependable application of AI systems in medication safety monitoring.

Drug safety surveillance is anticipated to become a more effective, predictive, and patient centered approach in the future when cutting edge AI technologies are integrated with international pharmacovigilance systems. To guarantee that AI is applied ethically and effectively in clinical practice, cooperation between regulatory bodies, medical personnel, and technology developers is essential to its successful adoption.

REFERENCE

1. World Health Organization. *The importance of pharmacovigilance: safety monitoring of medicinal products*. Geneva: World Health Organization, 2002.
2. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237): 1255–1259. https: //doi.org/10.1016/S0140-6736(00)02799-9
3. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ, 329(7456): 15. https: //doi.org/10.1136/bmj.329.7456.15
4. Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5): 385–396. https: //doi.org/10.2165/00002018-200629050-00003

5. World Health Organization. *Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre*. Uppsala: The Uppsala Monitoring Centre; 2000.
6. Salas, M., Petracek, J., Yalamanchili, P., Aimer, O., Kasthuril, D., Dhingra, S., Junaid, T., & Bostic, T. (2022). The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. Pharmaceutical Medicine, 36(5): 295–306. https: //doi.org/10.1007/s40290-022-00441-z
7. Kompa, B., Hakim, J. B., Palepu, A., Kompa, K. G., Smith, M., Bain, P. A., Woloszynek, S., Painter, J. L., Bate, A., & Beam, A. L. (2022). Artificial intelligence based on machine learning in pharmacovigilance: A scoping review. Drug Safety, 45(5): 477–491. https: //doi.org/10.1007/s40264-022-01176-1
8. Pilipiec, P., Liwicki, M., & Bota, A. (2022). Using machine learning for pharmacovigilance: A systematic review. Pharmaceutics, 14(2): Article 266. https: //doi.org/10.3390/pharmaceutics14020266
9. Zhao, Y., Yu, Y., Wang, H., Li, Y., Deng, Y., Jiang, G., et al. (2022). Machine learning in causal inference: Application in pharmacovigilance. Drug Safety, 45(5): 459–476. https: //doi.org/10.1007/s40264-022-01155-6
10. Aronson JK. Artificial intelligence in pharmacovigilance: An introduction to terms, concepts, applications, and limitations. *Drug Saf*. 2022; 45(5): 407-418. doi: 10.1007/s40264-022-01156-5.
11. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. *Pharm Med*., 2022; 36(5): 295-306. doi: 10.1007/s40290-022-00441-z.
12. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial intelligence based on machine learning in pharmacovigilance: A scoping review. *Drug Saf*. 2022; 45(5): 477-491. doi: 10.1007/s40264-022-01176-1.
13. Pilipiec P, Liwicki M, Bota A. Using machine learning for pharmacovigilance: A systematic review. *Pharmaceutics*, 2022; 14(2): 266. doi: 10.3390/pharmaceutics14020266.
14. Wang Y, Wang L, Rastegar-Mojarad M, et al. Clinical information extraction applications: A literature review. *J Biomed Inform*, 2018; 77: 34-49. doi: 10.1016/j.jbi.2017.11.011.
15. Sallam M. ChatGPT utility in healthcare education, research, and practice: Systematic review on the promising perspectives and valid concerns. *Healthcare (Basel)*., 2023; 11(6): 887. doi: 10.3390/healthcare11060887.

16. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. *Pharm Med*., 2022; 36(5): 295-306. doi: 10.1007/s40290-022-00441-z.
17. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial intelligence based on machine learning in pharmacovigilance: a scoping review. *Drug Saf*., 2022; 45(5): 477-491. doi: 10.1007/s40264-022-01176-1.
18. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic facts. *Drug Inf J*., 2008; 42(5): 409-419. doi: 10.1177/009286150804200501.
19. Wang Y, Wang L, Rastegar-Mojarad M, et al. Clinical information extraction applications: a literature review. *J Biomed Inform*, 2018; 77: 34-49. doi: 10.1016/j.jbi.2017.11.011.
20. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. *Clin Pharmacol Ther*., 2012; 91(6): 1010-1021. doi: 10.1038/clpt.2012.50.
21. Xu R, Wang Q. Automatic signal extraction, prioritizing, and filtering approaches in pharmacovigilance. *Pharm Med*., 2014; 28(6): 367-375. doi: 10.1007/s40290-014-0067-5.
22. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. *J Biomed Inform*, 2015; 54: 202-212. doi: 10.1016/j.jbi.2015.02.004.
23. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—What is it and what can it tell us? *N Engl J Med*., 2016; 375(23): 2293-2297. doi: 10.1056/NEJMsb1609216.
24. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. *Pharm Med*., 2022; 36(5): 295-306. doi: 10.1007/s40290-022-00441-z.
25. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial intelligence based on machine learning in pharmacovigilance: a scoping review. *Drug Saf*. 2022; 45(5): 477-491. doi: 10.1007/s40264-022-01176-1.
26. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. *Clin Pharmacol Ther*., 2012; 91(6): 1010-1021. doi: 10.1038/clpt.2012.50.
27. Xu R, Wang Q. Automatic signal extraction, prioritizing, and filtering approaches in pharmacovigilance. *Pharm Med*., 2014; 28(6): 367-375. doi: 10.1007/s40290-014-0067-5.

28. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. *J Biomed Inform*, 2015; 54: 202-212. doi: 10.1016/j.jbi.2015.02.004.
29. Nikfarjam A, Sarker A, O'Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: Mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. *J Am Med Inform Assoc*. 2015; 22(3): 671-681. doi: 10.1093/jamia/ocu041.
30. Zhao Y, Yu Y, Wang H, Li Y, Deng Y, Jiang G, et al. Machine learning in causal inference: application in pharmacovigilance. *Drug Saf*., 2022; 45(5): 459-476. doi: 10.1007/s40264-022-01155-6.
31. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. *Eur J Clin Pharmacol*., 1998; 54(4): 315-321. doi: 10.1007/s002280050466.
32. Topaz M, Seger DL, Slight SP, Goss F, Lai K, Wickner PG, et al. Rising drug safety concerns from FDA adverse event reporting system data: performance of pharmacovigilance signal-detection algorithms. *Drug Saf*., 2015; 38(6): 559-567. doi: 10.1007/s40264-015-0281-5.
33. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. *Clin Pharmacol Ther*., 2012; 91(6): 1010-1021. doi: 10.1038/clpt.2012.50.
34. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiol Drug Saf*., 2009; 18(6): 427-436. doi: 10.1002/pds.1742.
35. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. *Pharmacoepidemiol Drug Saf*., 2011; 20(1): 1-11. doi: 10.1002/pds.2053.
36. Friedman C. Discovering novel adverse drug events using natural language processing and mining of the electronic health record. *Clin Pharmacol Ther*., 2009; 85(5): 532-534. doi: 10.1038/clpt.2009.30.
37. Wang Y, Wang L, Rastegar-Mojarad M, Liu S, Shen F, Liu H. Clinical information extraction applications: a literature review. *J Biomed Inform*, 2018; 77: 34-49. doi: 10.1016/j.jbi.2017.11.011.

38. Bates DW, Saria S, Ohno-Machado L, Shah A, Escobar G. Big data in health care: using analytics to identify and manage high-risk and high-cost patients. *Health Aff (Millwood),* 2014; 33(7): 1123-1131. doi: 10.1377/hlthaff.2014.0041.
39. Zhao Y, Yu Y, Wang H, Li Y, Deng Y, Jiang G, et al. Machine learning in causal inference: application in pharmacovigilance. *Drug Saf*., 2022; 45(5): 459-476. doi: 10.1007/s40264-022-01155-6.
40. Pilipiec P, Liwicki M, Bota A. Using machine learning for pharmacovigilance: a systematic review. *Pharmaceutics*, 2022; 14(2): 266. doi: 10.3390/pharmaceutics14020266.
41. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. *Clin Pharmacol Ther.*, 2012; 91(6): 1010–1021. doi: 10.1038/clpt.2012.50.
42. Xu R, Wang Q. Automatic signal extraction, prioritizing, and filtering approaches in pharmacovigilance. *Pharm Med.,* 2014; 28(6): 367–375. doi: 10.1007/s40290-014-0067-5.
43. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA.,* 2018; 319(13): 1317–1318. doi: 10.1001/jama.2017.18391.
44. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med.,* 2019; 380(14): 1347–1358. doi: 10.1056/NEJMra1814259.
45. Ribeiro MT, Singh S, Guestrin C. "Why should I trust you?" Explaining the predictions of any classifier. *KDD.*, 2016; 1135–1144. doi: 10.1145/2939672.2939778.
46. Price WN, Cohen IG. Privacy in the age of medical big data. *Nat Med.*, 2019; 25(1): 37–43. doi: 10.1038/s41591-018-0272-7.
47. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. *N Engl J Med.* 2018; 378(11): 981–983. doi: 10.1056/NEJMp1714229.
48. U.S. FDA. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan. 2021.
49. European Medicines Agency (EMA). Reflection paper on use of artificial intelligence in the medicinal product lifecycle, 2023.
50. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.*, 2019; 25(1): 44–56. doi: 10.1038/s41591-018-0300-7.
51. FDA. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan. U.S. Food and Drug Administration; 2021.
52. European Medicines Agency (EMA). Reflection paper on use of artificial intelligence in the medicinal product lifecycle. EMA, 2023.

53. World Health Organization. Ethics and governance of artificial intelligence for health. WHO, 2021.
54. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthc J.*, 2019; 6(2): 94–98. doi: 10.7861/futurehosp.6-2-94.
55. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.*, 2019; 25(1): 44–56. doi: 10.1038/s41591-018-0300-7.
56. Obermeyer Z, Emanuel EJ. Predicting the future — big data, machine learning, and clinical medicine. *N Engl J Med.*, 2016; 375(13): 1216–1219. doi: 10.1056/NEJMp1606181.
57. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med.*, 2019; 380(14): 1347–1358. doi: 10.1056/NEJMra1814259.
58. Sallam M. ChatGPT utility in healthcare education, research, and practice: systematic review. *Healthcare (Basel).*, 2023; 11(6): 887. doi: 10.3390/healthcare11060887.
59. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA.*, 2018; 319(13): 1317–1318. doi: 10.1001/jama.2017.18391.
60. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. *N Engl J Med.*, 2018; 378(11): 981–983. doi: 10.1056/NEJMp1714229.